Gilead Sciences to acquire MYR GmbH

Prof. Dr. Stephan Urban. Source UK-HD

US pharmaceutical company Gilead buys MYR GmbH for 1.45 billion euros / MYR GmbH is licensee of the drug Hepcludex (Bulevirtide) developed by DZIF professor Dr Stephan Urban from Heidelberg / Hepcludex complements the portfolio of the US pharmaceutical giant with a drug against hepatitis D, which is urgently needed worldwide

Read full news (in German)

Recent Posts

See All


BioRN Network e.V.

Im Neuenheimer Feld 582

D-69120 Heidelberg

Contact us >>


BioRN is the science and industry cluster of the Rhine-Main-Neckar region around Heidelberg, one of Germany’s strongest biotech hubs. It is a non-profit network fostering health innovations, supporting a rich translational ecosystem and promoting, representing and connecting the regional innovation stakeholders.

  • LinkedIn Social Icon
  • Twitter Social Icon
  • YouTube Social  Icon

"Making Life Science matter...

...and Innovation happen!"


© Copyright - BioRN Network e.V. -  Imprint & Legal Notice - Data Privacy Policy